168 related articles for article (PubMed ID: 16490810)
21. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.
Nakajima M; Kuroiwa Y; Yokoi T
Drug Metab Rev; 2002 Nov; 34(4):865-77. PubMed ID: 12487152
[TBL] [Abstract][Full Text] [Related]
22. Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance.
Hukkanen J; Jacob P; Benowitz NL
Clin Pharmacol Ther; 2006 Nov; 80(5):522-30. PubMed ID: 17112808
[TBL] [Abstract][Full Text] [Related]
23. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.
Yamanaka H; Nakajima M; Nishimura K; Yoshida R; Fukami T; Katoh M; Yokoi T
Eur J Pharm Sci; 2004 Aug; 22(5):419-25. PubMed ID: 15265511
[TBL] [Abstract][Full Text] [Related]
24. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6.
Denton TT; Zhang X; Cashman JR
Biochem Pharmacol; 2004 Feb; 67(4):751-6. PubMed ID: 14757175
[TBL] [Abstract][Full Text] [Related]
25. A novel duplication type of CYP2A6 gene in African-American population.
Fukami T; Nakajima M; Yamanaka H; Fukushima Y; McLeod HL; Yokoi T
Drug Metab Dispos; 2007 Apr; 35(4):515-20. PubMed ID: 17267622
[TBL] [Abstract][Full Text] [Related]
26. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.
Yoshida R; Nakajima M; Nishimura K; Tokudome S; Kwon JT; Yokoi T
Clin Pharmacol Ther; 2003 Jul; 74(1):69-76. PubMed ID: 12844137
[TBL] [Abstract][Full Text] [Related]
27. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T
Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015
[TBL] [Abstract][Full Text] [Related]
28. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.
Mwenifumbo JC; Tyndale RF
Pharmacogenomics; 2007 Oct; 8(10):1385-402. PubMed ID: 17979512
[TBL] [Abstract][Full Text] [Related]
29. Effects of whole deletion of CYP2A6 on nicotine metabolism in humans.
Zhang X; Ameno K; Ameno S; Kinoshita H; Kubota T; Kumihashi M; Mostofa J; Iwahashi K; Ijiri I
Drug Chem Toxicol; 2002 May; 25(2):203-13. PubMed ID: 12024803
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of human liver microsomal (S)-nicotine oxidation by (-)-menthol and analogues.
MacDougall JM; Fandrick K; Zhang X; Serafin SV; Cashman JR
Chem Res Toxicol; 2003 Aug; 16(8):988-93. PubMed ID: 12924926
[TBL] [Abstract][Full Text] [Related]
31. [Role of cytochrome P450 2A6 polymorphism in nicotine metabolism and tobacco-dependent behaviour].
Xia XY; Peng RX
Yao Xue Xue Bao; 2004 Sep; 39(9):758-63. PubMed ID: 15606031
[No Abstract] [Full Text] [Related]
32. Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice.
Siu EC; Tyndale RF
Mol Pharmacol; 2007 Mar; 71(3):826-34. PubMed ID: 17158199
[TBL] [Abstract][Full Text] [Related]
33. Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica Gigas.
Yoo HH; Lee MW; Kim YC; Yun CH; Kim DH
Drug Metab Dispos; 2007 Oct; 35(10):1759-65. PubMed ID: 17620343
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
Zhang W; Kilicarslan T; Tyndale RF; Sellers EM
Drug Metab Dispos; 2001 Jun; 29(6):897-902. PubMed ID: 11353760
[TBL] [Abstract][Full Text] [Related]
35. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.
Swan GE; Benowitz NL; Lessov CN; Jacob P; Tyndale RF; Wilhelmsen K
Pharmacogenet Genomics; 2005 Feb; 15(2):115-25. PubMed ID: 15861035
[TBL] [Abstract][Full Text] [Related]
36. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
Nakajima M; Yokoi T
Drug Metab Pharmacokinet; 2005 Aug; 20(4):227-35. PubMed ID: 16141602
[TBL] [Abstract][Full Text] [Related]
37. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
Johnstone E; Benowitz N; Cargill A; Jacob R; Hinks L; Day I; Murphy M; Walton R
Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
[TBL] [Abstract][Full Text] [Related]
38. Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers.
von Weymarn LB; Chun JA; Hollenberg PF
Carcinogenesis; 2006 Apr; 27(4):782-90. PubMed ID: 16364922
[TBL] [Abstract][Full Text] [Related]
39. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice.
Siu EC; Tyndale RF
J Pharmacol Exp Ther; 2008 Mar; 324(3):992-9. PubMed ID: 18065502
[TBL] [Abstract][Full Text] [Related]
40. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
Malaiyandi V; Sellers EM; Tyndale RF
Clin Pharmacol Ther; 2005 Mar; 77(3):145-58. PubMed ID: 15735609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
